The Centers for Medicare and Medicaid Services plans to terminate four demonstration projects by the end of 2025, closing out ...

Generic drugmakers and hospital pharmacists warn that added financial pressure from tariffs could strain the nation's generic drug supplies.

Basically, a brand-name drug company settles a patent infringement lawsuit by paying cash or transferring something else of ...

A study found Indian generics sold in the US between 2009-2018 linked to a 54% higher risk of serious side effects compared ...

Pliant Therapeutics' PLN-101095 showed partial responses in ICI-refractory tumors, with a 50% ORR at the highest dose tested ...

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

The Indian Pharmaceutical Alliance refutes a study claiming Indian generic drugs have higher adverse events, stating quality ...

Alkem Laboratories has launched a generic medication for type-2 diabetes, chronic kidney disease and heart failure in India ...

Glenmark and Alkem Labs launched the generic version as well as its Fixed Dose Combination (FDCs) of Empagliflozin in India.

Mankind Pharma and other domestic companies have launched generic versions of the popular diabetes drug Empagliflozin at ...